Article

VIDEO: Richard Stefanacci, DO, Addresses Cost Concerns of Neurodegenerative Diseases

Conference|NAMCP: National Association of Managed Care Physicians Forum

Richard Stefanacci, DO, Associate Professor, Health Policy & Public Health, University of the Sciences, says there are 2 cost concerns associated with neurodegenerative diseases.

Richard Stefanacci, DO, Associate Professor, Health Policy & Public Health, University of the Sciences, says there are 2 cost concerns associated with neurodegenerative diseases. One is the actual cost of the disease and the second is the cost of diagnostic testing. Dr Stefanacci also says that treatments are now currently inexpensive, but with new emerging therapiess the costs will rise.

This video was taken on Thursday, November 8 at the NAMCP Fall Forum in Las Vegas, NV.

Related Videos
Milind Desai, MD
Masanori Aikawa, MD
Neil Goldfarb, GPBCH
Mabel Mardones, MD.
Mei Wei, MD, an oncologist specializing in breast cancer at Huntsman Cancer Institute at the University of Utah.
Alexander Mathioudakis, MD, PhD, clinical lecturer in respiratory medicine at The University of Manchester
Screenshot of Susan Wescott, RPh, MBA
Screenshot of an interview with Adam Colborn, JD
Screenshot of an interview with James Chambers, PhD
Screenshot of an interview with Megan Ehret, PharmD
Related Content
Semaglutide injectors. | Image Credit :Andreas Prott- stock.adobe.com
November 21st 2024

Semaglutide Eligibility Expands to Over Half of US Adults

Cameron Santoro
Over half of the US adult population may benefit from semaglutide, a drug primarily used for weight loss and diabetes, although concerns about access and cost persist, especially considering its potential for wider health applications.
Image of Managed Care Cast logo
August 29th 2023

The Importance of Examining and Preventing Atrial Fibrillation

Maggie L. Shaw
At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Blood test | Image: Edward Jenner for Pexels
November 18th 2024

KRAKEN: Oral Muvalaplin Safely Lowers Lp(a) in Early-Stage Trial

Mary Caffrey
Results bring more competition to treat this genetically driven target for cardiovascular risk.
Managed Care Cast.
June 28th 2022

Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions

Matthew Gavidia
On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Entresto packaging | Image credit: Novartis
November 18th 2024

Cardiomyopathy Risk Plummets When Sacubitril/Valsartan Taken With Chemo

Mary Caffrey
The SARAH trial was limited to high-risk patients, which the lead investigator said prevented unnecessary exposure to adverse events in patients less at risk of cardiomyopathy.
Kerendia press photo | Image credit: Bayer
November 18th 2024

Benefits of Finerenone Similar in Women and Men, Analysis Finds

Mary Caffrey
Follow-up results for the FINEARTS-HF trial focused on specific results for women and men, hyperkalemia risk, and an analysis of the elements of its composite end point.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo